David Southwell is the founder of TScan Therapeutics. TScan Therapeutics has raised $180M in total funding. Latest round: Series C.
David Southwell is the Chief Executive Officer at TScan Therapeutics, a biopharmaceutical company focused on developing T-cell receptor engineered T cell therapies in oncology. Under his leadership, TScan has raised a significant amount of funding to advance its TCR-T cell therapy pipeline for solid and liquid tumors into the clinic.
Full founder directory · Investor directory · Company funding database · Fundraising library